Authors
Latest:
Immunotherapy for NSCLC: Clinical PearlsFinal takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Latest:
Overcoming the Hurdles to EHR AdoptionA survey conducted by the Institute for Health Policy between late 2007 and early 2008 found that only 4% of physicians are using a fully functional EHR.
Latest:
Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AMLMark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.
Latest:
Dr. Ball on Eventual Role of Immunotherapy in Patients With RCCMark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.
Latest:
What Can We Learn From "Extreme Survivors" of Breast Cancer?Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.
Latest:
Dr. Mark Scholz on Advances in Prostate Cancer ImagingMark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.
Latest:
Dr. Duncan on Measuring the Success of Patient NavigationMark D. Duncan, MD, from The Johns Hopkins University School of Medicine, discusses demonstrable metrics that help measure the success of a patient navigation program.
Latest:
Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer LandscapeA panel of experts offer future perspectives in HR+ breast cancer.
Latest:
Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CISMark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Latest:
Dr. Mark Delworth on Robotic ProstatectomyMark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.
Latest:
Dr. Robson on the Potential Utility of Tucatinib in HER2+ Breast CancerMark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Dr. Emberton on Focal Therapy Techniques in Prostate CancerMark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.
Latest:
Dr. Emberton on the Importance of Multidisciplinary Care in Prostate CancerMark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.
Latest:
Future Implications of ctDNA in the Management of NSCLCA thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.
Latest:
Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic CancerMark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.
